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Development of castration-resistant prostate cancer (CRPC) in a low androgen environment, arising from androgen deprivation 
therapy (ADT), is a major problem in patients with advanced prostate cancer (PCa). Several mechanisms have been hypothesized to 
explain the progression of PCa to CRPC during ADT, one of them is so called persistent intratumoral steroidogenesis. The existence 
of intratumoral steroidogenesis was hinted based on the residual levels of intraprostatic testosterone (T) and dihydrotestosterone 
(DHT) after ADT. Accumulating evidence has shown that the intraprostatic androgen levels after ADT are sufficient to induce cancer 
progression. Several studies now have demonstrated that PCa cells are able to produce T and DHT from different androgen precursors, 
such as cholesterol and the adrenal androgen, dehydroepiandrosterone (DHEA). Furthermore, up-regulation of genes encoding key 
steroidogenic enzymes in PCa cells seems to be an indicator for active intratumoral steroidogenesis in CRPC cells. Currently, several 
drugs are being developed targeting those steroidogenic enzymes, some of which are now in clinical trials or are being used as 
standard care for CRPC patients. In the future, novel agents that target steroidogenesis may add to the arsenal of drugs for CRPC 
therapy.
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INTRODUCTION
Prostate cancer (PCa) is rated to be the second most preva-
lent malignancy in males worldwide. According to GLOBO-
CAN, in 2008 there were about 903,500 new cases of PCa and 
258,400 deaths of PCa worldwide [1]. The dependence of PCa 
on androgens, such as testosterone (T) and dihydrotestoster-
one (DHT), during early carcinogenesis and progression to 
metastatic disease has been broadly reported, and therefore 
androgen deprivation therapy (ADT) is given to reduce T and 
DHT levels [2]. During ADT, a reduction of serum T levels up 
to 90% is achieved after 2 to 4 weeks of treatment. However, 
most of the patients will develop a recurrence under low an-
drogen levels, that is called castration-resistant prostate cancer 
(CRPC) [3].
 Several mechanisms have been suggested to cause the 
progression of PCa to CRPC under ADT conditions, including 
hypersensitivity of the androgen receptor (AR) signaling path-
way to androgens, enrichment or accumulation of androgen-
insensitive stem cells, and activation of intratumoral steroido-
genesis [4]. Among these, the intratumoral steroidogenesis 
pathway has recently gained much attention and support. 
Although serum T levels decrease during ADT, it was shown 
that the intraprostatic androgen levels in CRPC patients was 
equal before and after ADT [5-8]. Based on this fact, it was hy-
pothesized, and later shown, that PCa cells are able to produce 
androgens itself via steroidogenesis [9], either by producing 
T and DHT from weak adrenal androgens (e.g., dehydroepi-




and survival [20]. In conclusion, current ADT strategies are not 
sufficient to reduce intraprostatic T and DHT to levels that can 
no longer activate AR signaling in prostate cancer cells [21].
 Although serum T and DHT levels are suppressed after ADT, 
serum levels of adrenal androgen precursors, such as DHEA 
(Table 1), remain constant after ADT (60–211 ng/dL vs. 90–203 
ng/dL before ADT) and was found to be the most abundant 
adrenal androgen in PCa tissue [5,22,23]. Measurement of in-
traprostatic DHEA levels are ~35 ng/g tissue in untreated PCa 
patients, while in ADT treated patients, intraprostatic DHEA 
levels are even slightly increased to ~48 ng/g tissue [24]. In the 
later study, androstenedione (AD) and androstenediol levels 
in PCa tissue after ADT were also shown to be similar to those 
in untreated PCa. AD and androstenediol levels in untreated 
PCa versus after ADT are ~0.125 ng/g tissue versus ~0.06 ng/g 
tissue and ~2.5 ng/g tissue versus ~3.5 ng/g tissue, respectively 
[24]. In summary, after ADT, the total androgen pool in the 
circulation is reduced by only 59% [25]. The remaining 41% of 
androgens, including DHEA, are still available in the prostate 
for the synthesis of T and DHT, which can stimulate prostate 
cancer after castration.
THE MECHANISM OF INTRATUMORAL 
STEROIDOGENESIS IN CRPC
Many studies have unraveled that intratumoral steroidogen-
esis could be initiated from weak adrenal androgens, such 
as DHEA or even by de novo androgen synthesis starting 
from cholesterol [10,11]. These androgen precursors are then 
converted to androgens, T and DHT. In the next part, we will 
discuss the possible mechanism of CRPC cells to synthesize 
androgens.
 Cholesterol is the natural precursor for androgen synthesis. 
It was reported that cholesterol levels could influence PCa 
progression. Xenograft tumors (derived from the LNCaP PCa 
cell line) in mice on a hypercholesterolemic diet were big-
ger and contained higher intratumoral T levels, compared 
to xenograft tumors in mice on a low fat/no cholesterol diet 
[11]. The enzymes required for de novo steroidogenesis from 
cholesterol, such as cytochrome P (CYP) 11A, CYP17A, and 
3β-hydroxysteroid dehydrogenase (3βHSD) 1 were detected 
androsterone [DHEA]) [10] or by de novo androgen synthesis 
starting from cholesterol [11]. It was also shown that several 
enzymes responsible for androgen synthesis are up regulated 
in CRPC tissue [12-14]. Due to the importance of intratumoral 
steroidogenesis to support the progression PCa to CRPC, 
new drugs are being developed that target the steroidogenic 
process, and hence may become new treatment options for 
CRPC. In this review, we will highlight the role of intratumoral 
steroidogenesis in CRPC and the status quo of developing 
novel targeted therapies for CRPC.
INTRATUMORAL STEROIDOGENESIS IN 
CRPC TISSUE
T and DHT are the main androgens for prostate cell differen-
tiation and homeostasis [15]. T is synthesized in Leydig cells, 
while DHT is mainly produced in prostate tissue. In primary 
and metastatic PCa, the dependence of prostate cells on an-
drogens persists, and androgens now directly support tumor 
cell proliferation, and hence tumor growth [16]. It was hypoth-
esized that diminishing serum androgen levels should lead to 
inhibition of PCa cell growth, and thus ADT was recommend-
ed for advanced or metastatic PCa [17]. Unfortunately, the 
lower serum androgen levels obtained during ADT were not 
accompanied by a reduction of intraprostatic androgen levels 
within the tumor. In many studies, serum and intraprostatic 
T and DHT levels prior and after ADT have been measured 
(Table 1) [5-8,18,19].
 Serum T levels are reduced significantly from 410–465 ng/dL 
to 11.5–13.4 ng/dL after ADT [7]. In contrast, intraprostatic T levels 
after ADT (0.74–1.44 ng/g tissue) [6,8] were equal to that prior 
to ADT (0.07–1.3 ng/g tissue) [18,19]. A decline in both serum 
and prostatic DHT levels were reported after ADT [7]. Prior to 
ADT, serum DHT levels ranged from 43.5–55.68 ng/dL, and 
after ADT, the serum DHT levels were dropped to 3.48–3.98 
ng/dL [7]. Prior to ADT, intraprostatic DHT levels ranged from 
4.6–6.4 ng/g tissue [7], and after ADT, prostatic DHT levels were 
reduced approximately 75% (1.0–1.9 ng/g tissue) [7]. Still, in vi-
tro and in vivo data indicate that these low intraprostatic DHT 
levels are sufficient to stimulate expression of androgen-reg-
ulated genes, and to support AR-mediated tumor-cell growth 
Table 1. Levels of T and DHT in serum and prostate tissue
Conditions
Serum (ng/dL) Prostate tissue (ng/g tissue)
T DHT DHEA T DHT DHEA
Before ADT 410–465 43.5–55.68 90–203 0.07–1.34 4.6–6.4 ~35
After ADT 11.5–13.4 3.48–3.98 60–211 0.74–1.44 1.0–1.9 ~48
T, testosterone; DHT, dihydrotestosterone; DHEA, dehidroepiandroseterone; ADT, androgen deprivation therapy.




uct, is produced by reduction of T, a reaction catalyzed by the 
5α-reductase (SRD5A) enzyme (Fig. 1; blue arrow). The classical 
pathway plays an essential role in intratumoral steroidogenesis 
and can be initiated from DHEA. In one of our studies [10], we 
have shown that DuCaP cells, a CRPC cell line model, are able 
to use DHEA as an androgen precursor. DuCaP cells were able 
to proliferate in DHEA-supplemented medium, an environ-
ment that resembles ADT. Furthermore, T and DHT were de-
tected in the medium soon after DHEA addition. These results 
suggested that these CRPC cells were able to convert DHEA into 
T and DHT, at levels sufficient to support cell growth.
 Several studies reported the up-regulation of key steroido-
genic enzymes involved in DHT synthesis via the classical 
pathway in prostate cancer tissue. In an in vivo study using LN-
CaP xenograft, examination of tumor homogenate of castrated 
mice revealed an increased expression of SRD5A1, an enzyme 
involved in the conversion of T into DHT [28]. In clinical CRPC 
samples, expression of aldo-keto reductase family 1 (AKR1) 
C3 and 17βHSD3 was increased, but SRD5A2 expression was 
decreased [13]. Similar results were found in metastatic CRPC 
samples that displayed up-regulation of AKR1C3 transcript lev-
els, and down-regulation of SRD5A2 expression [8]. In line with 
these findings in tissue samples, higher transcript expression 
levels of AKR1C3, SRD5A1, and SRD5A3 were found in circu-
lating tumor cells (CTC) derived from primary PCa. In CTC 
derived from CRPC patients, up-regulation of AKR1C3 and SR-
D5A1 transcript was detected. However, in both CTC samples, 
SRD5A2 transcript levels were decreased [12]. Since the SRD5A 
isoforms all possess similar SRD5A activity, elevated SRD5A1 
and/or SRD5A3 transcript levels suggest that PCa and CRPC 
cells actively convert T into DHT [12]. 
 Beside the classical pathway, the backdoor pathway provides 
an alternative production of DHT that bypasses the need of T 
as an intermediate (Fig. 1; red arrow). The backdoor pathway is 
primarily active during organogenesis in the fetus to produce 
sufficient amounts of DHT for male sex development, whereas 
it is less active in the adult male [29]. Active intratumoral ste-
roidogenesis via the backdoor pathway was demonstrated by 
the high conversion rate of androstenedione (AD) into DHT in 
CRPC cell lines and tissues from CRPC patients [30]. By treat-
ing CRPC cell lines with [3H]-AD and [3H]-T, followed by HPLC 
analysis, the conversion pathway, either AD → androstanedione 
(5α-dione) → DHT or AD → T → DHT, could be measured. The 
outcome of these studies showed that AD is more rapidly and 
uniformly converted into DHT via the backdoor pathway (i.e., 
via 5α-dione) than via the classical pathway (i.e., via T). Simi-
larly, fresh CRPC metastases exhibited robust conversion of AD 
→ 5α-dione → DHT [30]. In the same study, the essential role of 
in LNCaP tumors in these mice fed on a hypercholesterol diet. 
A high expression of CYP17A, the key enzyme for de novo an-
drogen synthesis, in tumor tissue was also correlated signifi-
cantly with cholesterol levels [11]. In a study using patient tis-
sue samples, metastatic CRPC exhibited significant increases 
in the expression levels of the FASN, CYP17A1, 3βHSD1, and 
3βHSD2 genes when compared to primary PCa [8]. Also, im-
munohistochemical staining for the CYP11A1, CYP17A1, and 
17β-hydroxysteroid dehydrogenase (17βHSD) 3 enzymes in 
lymph node metastasis showed a moderately higher staining 
intensity compared to primary PCa samples, indicating that 
all these enzymes are up-regulated in metastatic CRPC tissue 
[26]. The results above support the existence of intratumoral 
de novo steroidogenesis from cholesterol.
 Subsequently, de novo synthesized androgen precursors 
need to be converted into active androgens. In PCa, the mecha-
nism or pathway, by which androgen precursors are converted 
into T and DHT is under extensive investigation. Many studies 
have shown that in CRPC cells the androgens, T and DHT, can 
be synthesized via the classical and/or the backdoor pathways 
[27]. Fig. 1 illustrates the mechanism of intratumoral steroido-
genesis in CRPC tissue and the steroidogenic enzymes that are 
involved in each particular pathway.
 In the classical pathway, DHT, as a final androgen prod-
Fig. 1. The illustration of intratumoral steroidogenesis pathway 
in castration-resistant prostate cancer tissue. T and DHT can be 
produced from cholesterol or DHEA via either the classical 
pathway, indicated by blue arrows or using the backdoor path-
way, indicated by red arrows. The conversion of cholesterol into 
intermediate products is indicated by black arrows. Steroido-
genic enzymes involved in each conversion are indicated in 
blue capital letters. T, testosterone; DHT, dihydrotestosterone; 
DHEA, dehidroepiandroseterone. 




SRD5A1 in the backdoor pathway synthesis of DHT was shown 
by knockdown of the SRD5A1 gene in LNCaP and LAPC4 cells. 
Accumulation of AD after SRD5A1 knockdown suggested that 
the conversion of AD into DHT was blocked [30]. In an in vivo 
study, high DHT levels up to 28 folds compared to control lev-
els, were detected in tumors of CWR22R-bearing athymic mice 
after androstanediol dipropionate injection at the tumor site 
[31]. High conversion of androstanediol into DHT was corre-
lated with increased mRNA and protein levels of 17βHSD6, an 
enzyme required for DHT synthesis. These studies suggest that 
the backdoor pathway is remarkably active in PCa, and may be 
responsible for PCa progression to CRPC [31].
 In summary, multiple studies have shown that intratumoral 
steroidogenesis in CRPC cells is active. Both cholesterol and 
adrenal androgens, such as DHEA, are potential sources for 
the intratumoral synthesis of DHT. Albeit the possibility of 
using multiple routes for androgen synthesis, the conversion 
of DHEA via the backdoor pathway seems to be the major 
route to produce DHT. Regardless the pathway used for DHT 
synthesis, the same set of genes/enzymes are needed for the 
conversion of androgen precursors into DHT, and all of these 
genes, AKR1C3, 17βHSD3, and SRD5A1/3, were found up-
regulated in PCa cells.
THERAPEUTIC IMPLICATION AND 
TARGETED THERAPY 
The up-regulation of steroidogenic enzymes as shown in previ-
ous section is essential to maintain persistent intratumoral ste-
roidogenesis and become attractive targets for therapy. Numer-
ous compounds have been and are being developed to inhibit 
steroidogenic enzyme activity, yet only few of them accepted by 
the U.S. Food and Drug Administration (FDA) for clinical appli-
cation. One of the approved steroidogenic enzyme inhibitors for 
the treatment of CRPC is the CYP17A inhibitor, abiraterone, while 
some other inhibitors are still under intensive development, such 
as inhibitors of AKR1C3, 17βHSD3, and SRD5A. The current sta-
tus of development of these inhibitors is discussed below.
1. CYP17A inhibitors
The CYP17A enzyme plays an important role in androgen bio-
synthesis. It possesses 17α-hydroxylase and C17,20-lyase activi-
ties, with the C17,20-lyase  being the key enzyme that involves 
in DHEA biosynthesis by the adrenal glands and the testes 
as well as several conversions during intratumoral steroido-
genesis. Because of the central role of CYP17A in androgen 
synthesis (Fig. 1), it was hypothesized that specific inhibition 
of CYP17A enzyme activity may lead to clinical antitumor re-
sponses [32].
 Abiraterone is the only CYP17A inhibitor approved by the 
FDA (April 2011) for the treatment of metastatic CRPC that 
previously received docetaxel-based chemotherapy [32]. It is 
formulated as the prodrug of abiraterone acetate, a nonste-
roid, highly selective, and irreversible CYP17A inhibitor [33]. 
Strikingly, its nonspecific CYP17A inhibition leads to rise in 
mineralocorticoids [34]. Therefore, addition of prednisone or 
prednisolone as mineralocorticoid receptor antagonist during 
abiraterone therapy is needed to prevent mineralocorticoid 
excess syndrome (i.e., hypertension, hypokalemia, and lower-
limb edema) [35].
 In preclinical studies, intraperitoneal administration of 
abiraterone acetate in a rodent model resulted in inhibition 
of CYP17A activity as shown by reduced weight of the ventral 
prostate [36]. Approval of abiraterone by the FDA was based 
on the outcome of a multinational phase III clinical trial that 
included 1,195 CRPC patients who previously received che-
motherapy. In this study, oral administration of 1,000 mg 
abiraterone with 5-mg prednisone prolonged the patient 
overall survival by an average of 14.8 months and increased 
the prostate-specific antigen (PSA) response rate by 29% [37]. 
Nowadays, oral abiraterone acetate (Zytiga, Janssen Biotech 
Inc., Horsham, PA, USA) is used in combination with pred-
nisone or prednisolone in Europe and the United States for 
metastatic CRPC previously treated with docetaxel-containing 
chemotherapy [38].
 Recently, a novel selective CYP17A inhibitor with more 
potent inhibition of C17,20-lyase over 17α-hydroxylase activi-
ties was developed, namely TAK-700 (Orteronel, Takeda Ltd., 
Osaka, Japan) [39]. It is a nonsteroidal, reversible 17,20-lyase 
inhibitor that is five-fold more selective to inhibit C17,20-lyase 
activity than 17α-hydroxylase activity [40]. By selectively inhib-
iting C17,20-lyase activity, the need of prednisone supplementa-
tion would be reduced because of less influence on mineralo-
corticoid synthesis [39]. Administration of TAK-700 to intact 
male rats resulted in a reduction of serum T levels and prostate 
weight [41]. In a recent phases 1 and 2 trial in metastatic CRPC 
patients, dose-escalating toxicities were observed. In the phase 
2 efficacy study, treatment with 400-mg TAK-700, supplement-
ed with 5-mg prednisone, significantly reduced PSA, T, and cir-
culating DHEA-sulfate levels. A phase 3 study in chemotherapy 
naïve and postdocetaxel metastatic CRPC patients is ongoing 
[42]. In summary, inhibition of the CYP17A enzyme is an ap-
proved treatment for metastatic CRPC, and further improve-
ments of inhibitory compounds and treatment schedules are 
ongoing. 





The AKR1C enzyme family is involved in normal androgen 
metabolism and in intratumoral steroidogenesis. There 
are three AKR1C isoforms, namely AKR1C1, AKR1C2, and 
AKR1C3. Both AKR1C1 and AKR1C2 are involved in the in-
activation of DHT, whereas AKR1C3 converts AD and andro-
stanedione into active T and DHT, respectively (Fig. 1) [43]. A 
recent study reported that high AKR1C3 levels were detected 
in a subset of CRPC patients and related to tumor progression. 
Therefore, AKR1C3 could be used as a biomarker to monitor 
active intratumoral steroidogenesis in CRPC and considered 
as a potential therapeutic target [10]. 
 However, development of selective AKR1C3 inhibitors is 
challenging due to its >86% sequence identity with the other 
human members of the AKR1C subfamily, AKR1C1 and 
AKR1C2. Inhibition of AKR1C1 and 2 activities would inhibit 
DHT turnover, and hence promote proliferative signaling in 
the prostate. The first AKR1C3 inhibitors were developed in 
2005 from nonsteroidal anti-inflammatory drugs analogs, par-
ticularly indomethacin [44]. Later, additional selective AKR1C3 
compound were developed based on N-phenylanthranilic 
acid, such as 3-((4-(trifluoromethyl)phenyl)amino)benzoic 
acid and 3-((4-nitronaphthalen-1-yl)amino)benzoic acid [45-
47]. These compounds showed AKR1C3 selective inhibition in 
biochemical assays [46,47], but, so far, none of the developed 
compounds has been tested in CRPC cell line and tumor mod-
els. Therefore, the effect of AKR1C3 inhibitors on CRPC still 
remains to be elucidated and awaits the development of highly 
selective AKR1C3 inhibitors and extensive pre-clinical testing. 
3. 17βHSD3 inhibitors
The 17βHSD3 enzyme converts AD and androstanedione 
into T and DHT, respectively during androgen synthesis (Fig. 
1) [43]. In PCa, involvement of 17βHSD3 in intratumoral ste-
roidogenesis was proven using LNCaP cell line transfected 
with pCEP4.17βHSD3. Incubation of stable LNCaP[HSD3] 
clone with AD efficiently stimulated cell proliferation, suggest-
ing the active conversion of available AD by the cells [48]. Be-
sides, high levels of the 17βHSD3 expression in prostatic tissue 
derived from primary PCa and lymph node metastasis were 
observed, indicating its role in PCa and advance disease [26]. 
Therefore, development of 17βHSD3 inhibitors may be ben-
eficial in reducing disease progression and promoting survival 
of CRPC patients. 
 17βHSD3 inhibitors could be developed from different com-
pound structures. Coumarin compounds, such as oxazolidine-
diones and thiazolidinediones, were reported to exhibit 17βHSD3 
inhibitory activity at low nanomolar concentrations, with ac-
ceptable selectivity over other 17β-HSD isoenzymes [49,50]. The 
STX2171 compound is another novel selective nonsteroidal 
17βHSD3 inhibitor that has an IC50 of ~200 nM in a whole-cell as-
say in vitro [48,51]. In a preclinical study, STX2171 was able to sig-
nificantly reduce plasma T levels and xenografted tumor growth 
in castrated male MF-1 mice supplemented with the androgen 
precursor AD [51]. Thus, the development of selective inhibitors 
of 17βHSD3 show promising results, but the specificity and effi-
cacy of these new compounds needs to be validated in preclinical 
studies before going into clinical trials. 
4. SRD5A inhibitors
Other essential enzymes involved in intratumoral steroido-
genesis are SRD5A1, SRD5A2, and SRD5A3, all 3 belonging 
to the SRD5A family. The SRD5A1 and SRD5A2 are able to 
catalyze the conversion of T into DHT, whilst recombinant SR-
D5A3 protein is also able to do so in in vitro assays [43,52,53]. 
Inhibition of DHT synthesis by SRD5A inhibitors offers novel 
therapeutic options in CRPC therapy, because most of the 
SRD5A enzyme isoforms are expressed at higher levels in 
PCa cells compared to normal prostate cells [30]. Two SRD5A 
inhibitors are available in the clinic, namely finasteride and 
dutasteride that were approved by the FDA for the treatment 
of benign prostatic hyperplasia (BPH) [54,55]. Finasteride 
inhibits SRD5A type 2, while dutasteride selectively inhibits 
SRD5A type 1 and 2 enzymes [56,57]. Dutasteride is a 45 times 
more potent in inhibiting SRD5A1 and two times more potent 
in inhibiting SRD5A2 compared to Finasteride [57].
 Finasteride was shown to be ineffective in PCa and CRPC 
treatment with no difference in local recurrence or distant me-
tastasis [58]. Currently, studies focus on the use of dutasteride, 
marketed under the trade name Avodart (GlaxoSmithKlinex, 
Brentford, UK), to reduce intratumoral androgen levels [59,60]. 
By inhibiting both SRD5A1 and SRD5A2, a reduction of intra-
tumoral DHT is expected and may lead to tumor suppression 
[52]. In a double-blinded, randomized, parallel-group trial, 
dutasteride lowered intraprostatic DHT levels by 93% after 4 
months of treatment. The reduced DHT level with dutasteride 
was accompanied by a reciprocal increase in serum and intra-
prostatic T levels, suggesting that dutasteride provides near-
maximal suppression of intraprostatic DHT levels in PCa pa-
tients [61]. On the other hand, in CRPC patient, a phase II study 
of dutasteride reported that 14 out of 25 evaluable men had 
disease progression by 2 months, 9 had stable disease, and 2 
had partial response, indicating that dutasteride had restricted 
biochemical response in CRPC [62].
 The limited effect of dutasteride, that only inhibits SRD5A1 
and 2, could be caused by high expression of SRD5A3 observed 




in CRPC tissue samples [53]. The existence of SRD5A3 may 
actively convert androgen precursors into DHT as was shown 
in an in vivo study using castration-resistant CWR22 xenograft 
bearing mice. Incubation of tumor lysates with higher concen-
trations of dutasteride than clinically achieved demonstrated 
persistent biosynthesis of DHT most likely by uninhibited SR-
D5A3 activity [53]. In summary, inhibition of SRD5A enzyme 
activity, so far, has shown limited therapeutic effects on CRPC. 
Novel SRD5A3 inhibitors are required to be combined with 
dutasteride to completely block SRD activity in CRPC cells.
 
FUTURE DIRECTIONS
The progression of primary PCa into CRPC during ADT re-
mains a major hurdle to improve overall survival of PCa pa-
tients. Intratumoral steroidogenesis is an essential mechanism 
leading to disease progression (i.e., resistance to ADT). Intratu-
moral steroidogenesis fuels PCa cells with sufficient amounts 
of active androgens, T and DHT, in the low androgenic en-
vironment during ADT. The key steroidogenic enzymes that 
are up-regulated in CRPC become novel attractive targets for 
therapy to lower intraprostatic androgen levels.
 In the last decade, several enzyme inhibitors have been de-
veloped that inhibit specific enzymes involved in intratumoral 
steroidogenesis. Clinical trials showed promising results, and 
the CYP17A inhibitor, abiraterone, now is approved for the 
treatment of chemotherapy resistant CRPC. However, target-
ing single enzyme activity may be of limited use, due to the 
tumor’s ability to use different androgen precursor sources 
and steroidogenesis pathways to maintain T and DHT levels. 
Therefore, combination therapies, using inhibitors of different 
enzymes may be the most optimal strategy to reduce intra-
tumoral T and DHT levels, and hence to combat CRPC [63]. 
Moreover, combination therapy might allow the use of lower 
doses of enzyme inhibitors with subsequent reductions in side 
and/or toxic effects. At the end, preclinical and clinical studies 
are still needed to investigate individual and combinations of 
enzyme inhibitors for reducing intratumoral androgen levels 
in CRPC patients. 
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